Abstract
Background: Frovatriptan is a potent anti-migraine agent with unfavourable slow onset of action, available on the market as film-coated tablets.
Objective: Optimization, by Quality by Designs strategies, of an orally disintegrating tablet (ODT) formulation of frovatriptan aimed to make its oral administration easier and its dissolution faster than the commercial tablets, thus improving its effectiveness in migraine management.
Method: A screening D-optimal design was applied to investigate the effects of different levels of kind and amount of ODT special excipient and disintegrant agents (identified as the critical variables) on disintegration time (DT) and % drug dissolved at 30 s (%Diss), selected as the responses to optimize. The best excipients combination, emerged by the screening step, was in-depth investigated by a Response Surface Methodology.
Results: A design space was defined where every combination of the selected variables fulfilled the required values for the responses with P ≥ 95%. In particular, the optimized formulation (Pharmaburst® 60% and Na alginate 15%), showed DT = 1.62±0.08 s and %Diss= 9.02±0.47%, with good agreement between measured and calculated values. Moreover, the developed ODT complied with the USP uniformity weight and drug content requirements, exhibited proper hardness and low friability, and provided 100 % dissolved drug within 5 min.
Conclusion: A frovatriptan ODT formulation was successfully developed by Quality by Design. It represents an effective alternative to conventional tablets, allowing easier oral administration (also to paediatric and geriatric people) and very faster drug dissolution, enhancing patient compliance and facilitating an earlier treatment of migraine attacks.
Keywords: Dissolution rate, frovatriptan, migraine management, oral drug delivery, orally disintegrating tablets, quality by design.
Current Drug Delivery
Title:Development and Optimization by Quality by Design Strategies of Frovatriptan Orally Disintegrating Tablets for Migraine Management
Volume: 15 Issue: 3
Author(s): Natascia Mennini, Serena Orlandini, Sandra Furlanetto, Benedetta Pasquini and Paola Mura*
Affiliation:
- Department of Chemistry, School of Human Health Sciences, University of Florence, Via Schiff 6, Sesto Fiorentino I-50019, Florence,Italy
Keywords: Dissolution rate, frovatriptan, migraine management, oral drug delivery, orally disintegrating tablets, quality by design.
Abstract: Background: Frovatriptan is a potent anti-migraine agent with unfavourable slow onset of action, available on the market as film-coated tablets.
Objective: Optimization, by Quality by Designs strategies, of an orally disintegrating tablet (ODT) formulation of frovatriptan aimed to make its oral administration easier and its dissolution faster than the commercial tablets, thus improving its effectiveness in migraine management.
Method: A screening D-optimal design was applied to investigate the effects of different levels of kind and amount of ODT special excipient and disintegrant agents (identified as the critical variables) on disintegration time (DT) and % drug dissolved at 30 s (%Diss), selected as the responses to optimize. The best excipients combination, emerged by the screening step, was in-depth investigated by a Response Surface Methodology.
Results: A design space was defined where every combination of the selected variables fulfilled the required values for the responses with P ≥ 95%. In particular, the optimized formulation (Pharmaburst® 60% and Na alginate 15%), showed DT = 1.62±0.08 s and %Diss= 9.02±0.47%, with good agreement between measured and calculated values. Moreover, the developed ODT complied with the USP uniformity weight and drug content requirements, exhibited proper hardness and low friability, and provided 100 % dissolved drug within 5 min.
Conclusion: A frovatriptan ODT formulation was successfully developed by Quality by Design. It represents an effective alternative to conventional tablets, allowing easier oral administration (also to paediatric and geriatric people) and very faster drug dissolution, enhancing patient compliance and facilitating an earlier treatment of migraine attacks.
Export Options
About this article
Cite this article as:
Mennini Natascia , Orlandini Serena , Furlanetto Sandra , Pasquini Benedetta and Mura Paola *, Development and Optimization by Quality by Design Strategies of Frovatriptan Orally Disintegrating Tablets for Migraine Management, Current Drug Delivery 2018; 15 (3) . https://dx.doi.org/10.2174/1567201814666170606100536
DOI https://dx.doi.org/10.2174/1567201814666170606100536 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access to both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Extracellular vesicles as drug delivery systems
Extracellular vesicles (EVs) are membranous vesicles released from almost all types of cells into extracellular space. EVs are categorized into different types including exosome (~30-150 nm), microvesicle or microparticle (~100-1,000 nm), apoptotic body (~1,000-5,000 nm), and others produced by different mechanisms. Since EVs bear the molecules (e.g., specific lipids, carbohydrates, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emergence in Pyrazolines: Synthetic and Biological Perspective
The Natural Products Journal Leptin Reduces Infarct Size in Association with Enhanced Expression of CB2, TRPV1, SIRT-1 and Leptin Receptor
Current Neurovascular Research Properties and Recent Advantages of N,N’-dialkylimidazolium-ion Liquids Application in Electrochemistry
Current Analytical Chemistry Interferon-α Treatment in Systemic Mastocytosis
Current Drug Targets Brain SPECT with Perfusion Radiopharmaceuticals and Dopaminergic System Radiocompounds in Dementia Disorders
Current Alzheimer Research RNAi Silencing in Mouse Models of Neurodegenerative Diseases
Current Drug Delivery GSK3 Inhibitors and Disease
Mini-Reviews in Medicinal Chemistry Pharmacology of Sigma (σ) Receptor Ligands from a Behavioral Perspective
Current Pharmaceutical Design The Microbiota-Gut-Brain Axis in Neuropsychiatric Disorders: Pathophysiological Mechanisms and Novel Treatments
Current Neuropharmacology The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Current Cancer Drug Targets Beneficial Effects of Statins on Endothelial Dysfunction and Vascular Stiffness
Current Vascular Pharmacology The Effect of Temperature on the Interaction of Phenanthroline-based Ligands with G-quadruplex: In Silico Viewpoint
Combinatorial Chemistry & High Throughput Screening Editorial (Hot Topic: Renin-Angiotensin System in Neuronal Disease)
Current Hypertension Reviews Modulating Agents in Resistant Malaria
Drug Design Reviews - Online (Discontinued) Opioid Withdrawal Syndrome: Emerging Concepts and Novel Therapeutic Targets
CNS & Neurological Disorders - Drug Targets The Role of the Endoplasmic Reticulum in the Accumulation of β-Amyloid Peptide in Alzheimers Disease
Current Molecular Medicine The Vpu Protein: New Concepts in Virus Release and CD4 Down-Modulation
Current HIV Research Muscarinic Acetylcholine Receptors
Current Pharmaceutical Design Synthesis of Functionalized Aryleneethynylene Oligomers and Polymers for Organic Electronics by Pd-Catalyzed Coupling Reactions
Current Organic Synthesis The Application of PET Technique for the Development and Evaluation of Novel Antipsychotics
Current Pharmaceutical Design